Reported Saturday, Arcutis' Phase 2 INTEGUMENT-INFANT Trial Shows Zoryve Cream 0.05% Achieves 49% Clear Or Almost Clear Skin And 58.3% EASI-75 In Infants With Atopic Dermatitis

Arcutis reported positive results from its Phase 2 INTEGUMENT-INFANT trial for ZORYVE (roflumilast) cream 0.05%, showing that 49% of infants achieved clear or almost clear skin and 58.3% reached EASI-75 after four weeks of treatment for atopic dermatitis. The cream was well tolerated, with safety findings aligning with previous pediatric studies. Caregivers noted rapid itch improvement in nearly half of the infants within 10 minutes. Additional studies related to the ZORYVE portfolio will be presented in three poster sessions.